EMA launches voluntary pilot for sharing data from New Approach Methodologies to replace or reduce animal testing in non-clinical medicine development.
EMA - European Medicines Agency · EU-wide23 Jul 2026 PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – July 2026 Online Start date: 23 July 2026, 09:30 (CEST) End date: 23 July 2026, 10:30 (CEST)
EMA - European Medicines Agency · EU-wideDiscover how EMA is advancing women’s health in medicines development and regulation Developers can submit New Approach Methodologies data and receive tailored feedback Evidence based information addressing concerns, ...
EMA - European Medicines Agency · EU-wideEMA and the European Innovation Council and SMEs Executive Agency (EISMEA) have strengthened their cooperation in support of health innovation in the European Union (EU). Today, EMA’s Executive Director Emer Cooke and...
EMA - European Medicines Agency · EU-wide17 Aug 2026 Committee for Medicinal Products for Human Use (CHMP): 17-20 August 2026 European Medicines Agency, Amsterdam, the Netherlands Start date: 17 August 2026 End date: 20 August 2026
EMA - European Medicines Agency · EU-wide12 Aug 2026 Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party Online Start date: 12 August 2026, 09:30 (CEST) End date: 12 August 2026, 13:00 (CEST)
EMA - European Medicines Agency · EU-wideBrussels, 14 July 2026Check against delivery (The published text is based on the prepared speech. Minor differences may have occurred during delivery)Dear Ms Jerkovic, dear…
EMA - European Medicines Agency · EU-wideReview will assess risk of leukoencephalopathy, a condition affecting the brainEMA’s safety committee (PRAC) has started a review of medicines containing levamisole, authorised in…, Agenda Agenda of the...
EMA - European Medicines Agency · EU-wideEMA warns of serious health risks from illegal GLP-1 receptor agonist medicines marketed for weight loss and diabetes.
EMA - European Medicines Agency · EU-widePRAC agrees new safety information on desogestrel- and etonogestrel-containing contraceptives and Litfulo, a medicine to treat alopecia areata Desogestrel- and etonogestrel-…, Agenda ...
EMA - European Medicines Agency · EU-wideEvidence based information addressing concerns, questions and false claims about vaccines Explores how EMA supports innovative alternatives to animal studies Experts discuss clinical trials, treatments and vaccines
EMA - European Medicines Agency · EU-wideFeatured information for European Academics and researchers in the field of medicine development.
EMA - European Medicines Agency · EU-wideOur Medicine finder above helps you find information on medicines authorised for human or veterinary use. You can find these by including the medicine's name or its active substance. It shows you information on centra...
EMA - European Medicines Agency · EU-wide31 Aug 2026 Pharmacovigilance Risk Assessment Committee (PRAC): 31 August - 3 September 2026 European Medicines Agency, Amsterdam, the Netherlands Start date: 31 August 2026 End date: 3 September 2026
EMA - European Medicines Agency · EU-wideFind all new and updated information published on our website in one place below. Filters are available to narrow results down based on your interests, such as whether it relates to human or veterinary medicines or sp...
EMA - European Medicines Agency · EU-wide08 Sep 2026 Committee for Orphan Medicinal Products (COMP): 8-10 September 2026 European Medicines Agency, Amsterdam, the Netherlands Start date: 8 September 2026 End date: 10 September 2026
EMA - European Medicines Agency · EU-wide08 Sep 2026 Paediatric Committee (PDCO): 8-11 September 2026 Online European Medicines Agency, Amsterdam, the Netherlands Start date: 8 September 2026 End date: 11 September 2026
EMA - European Medicines Agency · EU-wideThe first meeting organised with APIC in the context of in the context of EMA's annual bilateral meetings with industry stakeholder organisations.
EMA - European Medicines Agency · EU-wideEMA's Pharmacovigilance Risk Assessment Committee initiates safety review of levamisole to assess risk of leukoencephalopathy.
EMA - European Medicines Agency · EU-wide08 Sep 2026 Committee for Medicinal Products for Veterinary Use (CVMP): 8-10 September 2026 European Medicines Agency, Amsterdam, the Netherlands Start date: 8 September 2026 End date: 10 September 2026
EMA - European Medicines Agency · EU-wideEMA’s Head of the Stakeholders and Communication Division Melanie Carr has been assigned Deputy Executive Director duties as of 1 August 2026. Since 2021, this role has been held by Ivo Claassen, Head of the Veterinar...
EMA - European Medicines Agency · EU-wideBoard’s decision concludes renewal process
EMA - European Medicines Agency · EU-wideEMA recommended marketing authorisation for Susvimo (ranibizumab) for wet AMD in combination with a refillable implant.
EMA - European Medicines Agency · EU-wideEMA recommended marketing authorisation for Icotyde (icotrokinra), an oral interleukin-23 receptor inhibitor, for moderate-to-severe plaque psoriasis in adults and adolescents aged 12+ weighing ≥40 kg.
EMA - European Medicines Agency · EU-wideEMA's CHMP has initiated a phased review of daraxonrasib for metastatic pancreatic cancer treatment.
EMA - European Medicines Agency · EU-wideCHMP recommended marketing authorisations for twelve medicines including three for hypercholesterolaemia and mixed dyslipidaemia.
EMA - European Medicines Agency · EU-wideEMA recommends withdrawal of Tavneos marketing authorisation because benefits no longer outweigh risks.
EMA - European Medicines Agency · EU-wideCommittee adopted positive opinions for one new veterinary medicine (Bexatil) and two variations (Mometamax Ultra, Cimalgex) updating adverse event frequencies.
EMA - European Medicines Agency · EU-wide